Oragenics - OGEN STOCK NEWS

Oragenics, Inc. (NYSE American: OGEN) announced that its reconvened Annual Meeting on January 25, 2022 was again adjourned due to insufficient quorum. The meeting has been rescheduled to February 25, 2022, at 4:00 p.m. Eastern Time. Currently, approximately 40% of outstanding shares have submitted proxies. The company has engaged Alliance Advisors to assist in soliciting votes. Shareholders are encouraged to vote by February 24, 2022, to achieve the required majority for proposals in the proxy statement filed on October 13, 2021.

Oragenics, Inc. (NYSE American: OGEN) has extended its licensing and collaboration agreement with the National Research Council of Canada to develop an intranasal vaccine targeting the SARS-CoV-2 Omicron variant. This partnership enables rapid production of spike protein antigens, reducing production time from months to weeks. Oragenics has shown promising results in preclinical studies, demonstrating protection in hamsters against SARS-CoV-2, paving the way for future human clinical trials.

Oragenics, Inc. (NYSE American: OGEN) will participate in Alliance Global Partners' Virtual Series on December 14, 2021, at 1:00 p.m. Eastern time. Executive Chairman Frederick W. Telling, Ph.D., will be interviewed about the Company’s Terra CoV-2 program and its SARS-CoV-2 vaccine candidate. Interested parties can register for the live webcast and replay requests can be made via email. Oragenics focuses on combating infectious diseases with its lead product, Terra CoV-2, aimed at preventing COVID-19 and its variants.

Oragenics, Inc. (AMEX: OGEN), in collaboration with Florida International University, published a study on antimicrobial lanthipeptides in the Journal of Chemical Theory and Computation. The research highlights the urgent need for new antibiotics amidst rising resistance to current treatments. Oragenics is developing lantibiotics that affect bacterial cell walls and membranes, showcasing their potential against antibiotic-resistant infections. The company aims to broaden its lantibiotic pipeline to combat Gram-negative infections while advancing its COVID-19 vaccine candidate, Terra CoV-2.

Oragenics, Inc. (NYSE American: OGEN) announced positive results from a hamster challenge study assessing its SARS-CoV-2 vaccine candidate. Both intranasal and intramuscular formulations demonstrated robust immune responses, successfully reducing viral loads to undetectable levels. The company plans to focus on the intranasal delivery route, citing advantages such as ease of distribution and potential for mucosal immunity. This study will support their Investigational New Drug filing to the FDA, expected in Q2 2022, advancing the program into human clinical trials.

Oragenics, Inc. (NYSE American: OGEN) announced the adjournment of its Annual Meeting of Shareholders originally scheduled for November 22, 2021, due to insufficient quorum. The meeting will reconvene on January 25, 2022, at 4:00 p.m. ET, to allow more time for shareholders to vote on proposals detailed in the proxy statement filed with the SEC on October 13, 2021. Currently, only 40% of shares are represented by proxy. Shareholders are encouraged to vote by January 24, 2022, at 11:59 p.m. ET. The company is enlisting Alliance Advisors to help secure the necessary votes.

Oragenics (NYSE American: OGEN) has been awarded a $250,000 small business innovation research grant for its lantibiotics research. The funding will support the development of novel antibiotics addressing ESKAPE pathogens, which are increasingly resistant to existing treatments. The grant, part of the National Institutes of Health's initiative, emerges amidst rising antibiotic resistance and aims to enhance the company’s R&D capabilities in collaboration with Florida International University. Executive Chairman Frederick W. Telling expressed optimism about the potential of lantibiotics in combating life-threatening infections.

Oragenics, Inc. (NYSE American: OGEN) has launched a study to evaluate the immunogenicity and viral load reduction of its SARS-CoV-2 vaccine candidate, Terra CoV-2, using novel adjuvants for both intranasal and intramuscular formulations. The hamster challenge study aims to assess cross-neutralization against COVID-19 variants, with results expected in November. These findings will contribute to the Investigational New Drug filing with the FDA, anticipated in Q1 2022, to advance into human clinical trials.

Oragenics, Inc. (NYSE American: OGEN) announces promising results in its COVID-19 vaccine development, utilizing a stabilized pre-fusion spike protein trimer that generates neutralizing antibodies in mice. Collaborating with NIH, the company is advancing candidates for a hamster viral challenge study, set to begin this month. OGEN plans to submit an IND application for its Terra CoV-2 vaccine in Q1 2022, confident in the immunogenicity of its novel adjuvants. The firm aims to improve vaccine development speed, addressing potential COVID-19 variants amidst ongoing public health challenges.